{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:51:03Z","timestamp":1770918663404,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155234","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T13:48:16Z","timestamp":1463060896000},"page":"e0155234","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings"],"prefix":"10.1371","volume":"11","author":[{"given":"Cosmin Sebastian","family":"Voican","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Corruble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Perlemuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Colle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2174\/138161205774414510","article-title":"Why drugs fail\u2014a study on side effects in new chemical entities","volume":"11","author":"D Schuster","year":"2005","journal-title":"Curr Pharm Des"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury","volume":"58","author":"S Verma","year":"2009","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"GP Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs\u2014II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"C Benichou","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method","volume":"51","author":"DC Rockey","year":"2010","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis","volume":"26","author":"VA Maria","year":"1997","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"CA Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","article-title":"Antidepressant-induced liver injury: a review for clinicians","volume":"171","author":"CS Voican","year":"2014","journal-title":"Am J Psychiatry"},{"key":"ref9","unstructured":"produit. VRdcd. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.servier.fr\/download\/VALDOXAN\/RCP_VALDOXAN.pdf\" xlink:type=\"simple\">http:\/\/www.servier.fr\/download\/VALDOXAN\/RCP_VALDOXAN.pdf<\/ext-link>. 2011."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncpendmet0505","article-title":"Nonalcoholic fatty liver disease: from pathogenesis to patient care","volume":"3","author":"G Perlemuter","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/11533280-000000000-00000","article-title":"The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications","volume":"24","author":"RS McIntyre","year":"2010","journal-title":"CNS Drugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2337\/dc10-1644","article-title":"Metabolic syndrome and onset of depressive symptoms in the elderly: findings from the three-city study","volume":"34","author":"TN Akbaraly","year":"2011","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/wps.20260","article-title":"Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort","volume":"14","author":"E Corruble","year":"2015","journal-title":"World Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"F Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"V Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"G Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.22442","article-title":"Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury","volume":"48","author":"J Rochon","year":"2008","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"UM Zanger","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00702-014-1273-4","article-title":"Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors","volume":"122","author":"F Gressier","year":"2015","journal-title":"J Neural Transm"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/humu.10280","article-title":"CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR","volume":"22","author":"E Schaeffeler","year":"2003","journal-title":"Hum Mutat"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2010.12.014","article-title":"Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and\/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA)","volume":"131","author":"L Boschloo","year":"2011","journal-title":"J Affect Disord"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference","volume":"37","author":"BA Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2125.1999.00952.x","article-title":"Transaminase elevation on placebo during phase I trials: prevalence and significance","volume":"48","author":"P Rosenzweig","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1365-2125.2003.01969.x","article-title":"The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit","volume":"57","author":"L Purkins","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"C Sgro","year":"2002","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","article-title":"Incidence of drug-induced liver injury in medical inpatients","volume":"61","author":"Y Meier","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4088\/JCP.v63n0208","article-title":"Hepatotoxicity associated with the new antidepressants","volume":"63","author":"A Carvajal Garcia-Pando","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0016-5085(88)90631-2","article-title":"Amitriptyline-induced prolonged cholestasis","volume":"94","author":"D Larrey","year":"1988","journal-title":"Gastroenterology"},{"key":"ref30","first-page":"1225","article-title":"Chronic hepatitis related to use of fluoxetine","volume":"92","author":"DE Johnston","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-118-10-199305150-00006","article-title":"Chronic active hepatitis associated with trazodone therapy","volume":"118","author":"PL Beck","year":"1993","journal-title":"Ann Intern Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","article-title":"Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance","volume":"27","author":"LK Teh","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11096-013-9783-y","article-title":"CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention","volume":"35","author":"M Mejin","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/10408360701713112","article-title":"Relevant issues in the monitoring and the toxicology of antidepressants","volume":"45","author":"SM Wille","year":"2008","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1373\/clinchem.2004.041327","article-title":"Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy","volume":"51","author":"W Steimer","year":"2005","journal-title":"Clin Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1365-2125.1999.00913.x","article-title":"Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers","volume":"47","author":"T Fukuda","year":"1999","journal-title":"Br J Clin Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T11:47:24Z","timestamp":1567856844000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155234"}},"subtitle":[],"editor":[{"given":"Vincent","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155234","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]}}}